Condition: KRAS P.G12C · Sponsor: D3 Bio (Wuxi) Co., Ltd
This is a first-in-human (FIH), multicenter, open-label, dose-escalation, and dose-expansion Phase 1/2 clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of D3S-001 or combination therapy in subjects with advanced KRAS p.G12C mutant solid tumors. D3S-001 will be taken daily by oral administration in 21-day treatment cycles.
This description comes directly from the study's public registry record.
Medical Director · +86 21 61635900 · D3bio_CT@d3bio.com
Always discuss trial participation with your own doctor first.
| D3 Bio Investigative Site 0402 | Orange, California, United States | Recruiting |
| D3 Bio Investigative Site 0407 | Palo Alto, California, United States | Recruiting |
| D3 Bio Investigative Site 0404 | Denver, Colorado, United States | Recruiting |
| D3 Bio Investigative Site 0406 | Sarasota, Florida, United States | Recruiting |
| D3 Bio Investigative Site 0401 | Detroit, Michigan, United States | Recruiting |
| D3 Bio Investigative Site 0405 | Nashville, Tennessee, United States | Recruiting |
| D3 Bio Investigative Site 0403 | Houston, Texas, United States | Recruiting |
| D3 Bio Investigative Site 0102 | Sydney, New South Wales, Australia | Recruiting |
| D3 Bio Investigative Site 0101 | Malvern, Victoria, Australia | Recruiting |
| D3 Bio Investigative Site 0105 | Melbourne, Victoria, Australia | Recruiting |
| D3 Bio Investigative Site 0103 | Nedlands, Western Australia, Australia | Recruiting |
| D3 Bio Investigative Site 0104 | Bedford Park, Australia | Recruiting |
+ 40 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05410145